| # | Drug | Count |
|---|---|---|
| 0 | PALBOCICLIB | 10612 |
| 1 | LETROZOLE | 2791 |
| 2 | LETROZOLE TABLETS | 2439 |
| 3 | FULVESTRANT | 2130 |
| 4 | SUNITINIB MALATE | 2020 |
| 5 | CARBOPLATIN | 1703 |
| 6 | CYCLOPHOSPHAMIDE | 1608 |
| 7 | CYCLOPHOSPHAMIDE FOR INJECTION | 1608 |
| 8 | CYCLOPHOSPHAMIDE INJECTION, SOLUTION | 1608 |
| 9 | CAPECITABINE | 1363 |
| # | Drug | Count | Frequency |
|---|---|---|---|
| 0 | BEVACIZUMAB-BVZR | 82 | 0.1163 |
| 1 | DYCLONINE HYDROCHLORIDE | 11 | 0.1158 |
| 2 | PALBOCICLIB | 10612 | 0.1110 |
| 3 | DACOMITINIB | 78 | 0.1041 |
| 4 | TALAZOPARIB | 171 | 0.0923 |
| 5 | CRIZOTINIB | 1110 | 0.0871 |
| 6 | LORLATINIB | 620 | 0.0832 |
| 7 | DORDAVIPRONE | 9 | 0.0698 |
| 8 | AXITINIB | 1324 | 0.0677 |
| 9 | FULVESTRANT | 2130 | 0.0636 |
| # | Drug class | Count |
|---|---|---|
| 0 | Kinase Inhibitor [EPC] | 16263 |
| 1 | Aromatase Inhibitor [EPC] | 3893 |
| 2 | Platinum-based Drug [EPC] | 3163 |
| 3 | Nucleoside Metabolic Inhibitor [EPC] | 2952 |
| 4 | Corticosteroid [EPC] | 2698 |
| 5 | Alkylating Drug [EPC] | 2350 |
| 6 | Estrogen Receptor Antagonist [EPC] | 2208 |
| 7 | Microtubule Inhibitor [EPC] | 1791 |
| 8 | Nonsteroidal Anti-inflammatory Drug [EPC] | 1494 |
| 9 | Vascular Endothelial Growth Factor Inhibitor [EPC] | 1369 |
| # | Drug class | Count | Frequency |
|---|---|---|---|
| 0 | Protease Activator [EPC] | 9 | 0.0698 |
| 1 | Estrogen Receptor Antagonist [EPC] | 2208 | 0.0545 |
| 2 | CD22-directed Immunoconjugate [EPC] | 155 | 0.0518 |
| 3 | Aromatase Inhibitor [EPC] | 3893 | 0.0342 |
| 4 | Kinase Inhibitor [EPC] | 16263 | 0.0292 |
| 5 | Provitamin D2 Compound [EPC] | 784 | 0.0263 |
| 6 | Glycolipid Disialoganglioside-directed Antibody [EPC] | 28 | 0.0258 |
| 7 | Gamma Secretase Inhibitor [EPC] | 23 | 0.0249 |
| 8 | Bispecific gp100 Peptide-HLA-directed CD3 T Cell Engager [EPC] | 15 | 0.0249 |
| 9 | Interleukin-6 Antagonist [EPC] | 13 | 0.0200 |